Colleen Koski

Recent Posts

Trio Resources (TRII) Begins Automating Mineral Processing

Posted by Colleen Koski

October 24, 2013 at 11:55 AM

Earlier this week, Trio Resources, Inc. (TRII-OTC) announced that it has started the process of automating a mill that was recently purchased for its Duncan-Kerr Property. Trio is a Canadian exploration-stage and small-scale processing company focused on developing the current mineral potential of historically rich mining regions. 

Read More

Topics: Trio Resources

T3 Motion Creates National Service Program for its Electric Vehicles

Posted by Colleen Koski

October 23, 2013 at 5:11 PM

Yesterday, T3 Motion, Inc. (TTTM-OTC) announced plans to offer service and preventative maintenance for its electric vehicles through a nationwide program—known as T3 Fleet Services. The program is set to launch November 1st in the Western region of the U.S., with plans to expand services nationally by year’s end.

The benefits of the T3 Fleet Services program include:

Read More

Topics: T3 Motion

Neonode (NEON): Next-Gen Chip Release and New Markets Fuel Growth

Posted by Colleen Koski

October 21, 2013 at 9:37 AM

Neonode Inc. (NEON-NASDAQ), a company that specializes in touch-sensing technologies for electronic devices, continues to improve its proprietary platform technology while expanding its potential applications. The Company’s patented MultiSensing® Technology enables users to interact with electronic devices by touching areas on a screen. Neonode’s technology recognizes any object (e.g., finger, stylus) and supports multiple touches on the screen simultaneously. It can sense an object’s size, pressure on a surface, depth, velocity, or proximity to the screen’s surface.

Second-Gen Chip Improves Touchscreen Performance, Cost, and Function

Read More

Topics: Neonode Inc.

CardioComm’s HeartCheck™ Proven Valuable in Large-Scale Study

Posted by Colleen Koski

October 18, 2013 at 10:13 AM

Read More

Topics: CardioComm Solutions

ISCO: New Preclinical Data, Continued Progress for Parkinson's Program

Posted by Colleen Koski

October 16, 2013 at 11:53 AM

International Stem Cell Corp. (ISCO-OTCQB) has announced new results from its preclinical Parkinson's disease program. ISCO is developing a novel approach that uses self-renewing human parthenogenetic neural stem cells (hPNSCs), which are derived from the Company’s proprietary histocompatible human pluripotent stem cells, to treat Parkinson’s disease. Parkinson's disease is a progressive disorder of the nervous system that affects four million to six million people worldwide (Source: National Parkinson Foundation). It belongs to a group of motor system disorders that result from the loss of dopamine-producing cells in the brain.

ISCO is currently evaluating its Parkinson's therapy in final preclinical primate studies. Data collected as part of a collaboration with the Sanford Burnham Medical Research Institute, summarized below, was announced at the American Neurological Association's 2013 Annual Meeting in New Orleans.

  • The neural stem cells were shown to migrate a significant distance from the site of implantation (in the striatum) to the main region where the loss of dopamine-releasing (“dopaminergic”) neurons occurs in Parkinson's patients—the substantia nigra. No evidence of migration outside the brain was observed.
  • Regarding safety, ISCO’s neural stem cells elicited a lower immunogenic response versus other cell types included in the study.
  • The study conclusively demonstrated that the neural stem cells were able to differentiate into the specific type of neurons lost in Parkinson’s disease.
Read More

Topics: ISCO

LRAD's Acoustic Hailing Devices to Aid in N. Colorado Flood Relief Efforts

Posted by Colleen Koski

September 19, 2013 at 11:47 AM

LRAD Corp. (LRAD-NASDAQ) has announced that it has loaned six acoustic hailing devices (AHDs) to the National Guard to aid in relief efforts following the massive flood in Northern Colorado. At least eight individuals were killed by the flooding and hundreds more remain missing. The flood caused an estimated $2 billion in property damage to buildings, roads, power and phone lines and other infrastructure in the area, hindering communication as well as search and rescue efforts.

Read More

Topics: LRAD

ISCO Teams Up with Duke for Clinical Research in Parkinson's Disease

Posted by Colleen Koski

August 21, 2013 at 12:07 PM

Earlier today, International Stem Cell Corporation (ISCO-OTC) announced that it has signed a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product. The research is expected to be coordinated by the Duke Clinical Research Institute (DCRI) and led by Mark Stacy, M.D., vice dean for clinical research, neurology at Duke University School of Medicine and one of the preeminent experts on neurology, having published more than 100 peer-reviewed scientific papers on Parkinson's disease and other movement disorders. The collaboration with DCRI also provides ISCO with access to Duke's clinical expertise in cell therapy clinical trials as well as an extensive patient population, giving the Company an opportunity to evaluate its stem cell therapy in Parkinson's disease.

Read More

Topics: ISCO

CardioComm Partner to Promote Case Study on SMART Monitoring Services

Posted by Colleen Koski

August 19, 2013 at 1:40 PM

Earlier today, CardioComm Solutions, Inc. (EKG-TSX.V) announced that its partner, SunGard Availability Services (Canada) Ltd, is expected to promote a case study evaluating CardioComm’s use of SunGard’s cloud-based systems infrastructure as the platform for the Company's HeartCheck™ SMART Monitoring services. The case study serves as an external confirmation of CardioComm’s technical capabilities and is part of the Company’s efforts to secure independent validation of its HeartCheck™ SMART Monitoring solution.  The companies signed a three-year partnership agreement in September 2012, which enabled CardioComm to use SunGard’s enterprise cloud services as the systems infrastructure to launch its HeartCheck™ SMART Monitoring services and the associated ECG Coordinating Centre (C4) in North America.

CardioComm’s HeartCheck™ SMART Monitoring services are designed to support consumers who seek to prevent or manage cardiac disease by enabling these patients to track their ECGs anytime and anywhere in the world. The HeartCheck™ PEN (shown below) is currently being sold for $259 for the device. Each customer who purchases a HeartCheck™ PEN is also offered one complimentary ECG report provided by call center (C4) physicians, which encourages the patient to establish a relationship with a C4 physician and also serves as a baseline ECG reading for future reference. Subsequent ECG readings are charged on a per-use basis.

Read More

Topics: CardioComm Solutions

FULL VIDEO (Reuters TV): Biotech Stocks To Watch and More

Posted by Colleen Koski

August 15, 2013 at 1:25 PM

Last week, Jeff Kraws sat down with Rhonda Schaffler at Reuters to discuss opportunities and trends in the biotech space. Mr. Kraws is a veteran Wall Street sell-side analyst with more than 20 years of experience and is also cofounder and CEO of Crystal Research Associates. If you enjoyed the short clip of this interview released earlier this week, the full segment (available below) goes into more detail on individual biotech stocks and the events every investor should be watching out for.

Read More

Topics: AtheroNova, Crystal Research Associates, Unilife Corp., biotech, MetaStat, Reuters

NEW RESEARCH: 72-page Report on International Stem Cell Corp. (ISCO)

Posted by Colleen Koski

August 6, 2013 at 11:00 AM

Yesterday, Crystal Research Associates initiated coverage on International Stem Cell Corporation (ISCO-OTC) with the release of a 72-page Executive Informational Overview® (What is an EIO?). The full report is available for download here.

International Stem Cell Corporation (“ISCO” or “the Company”) is a biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and the eye, as well as on the development and commercialization of cell-based research and cosmetic products.

ISCO’s Novel Stem Cell Technology 

ISCO is pioneering the development of a new class of stem cells—known as human parthenogenetic stem cells (hpSCs). The Company believes that these therapeutic stem cells avoid the safety, economic, and ethical concerns inherent with existing stem cell technologies. 

ISCO’s core proprietary technology, parthenogenesis, refers to a form of asexual reproduction in which an egg develops without being fertilized by a male gamete. The creation of hpSCs involves the stimulation of a human oocyte (egg) to start the cell division process without actual fertilization. Since the eggs are not fertilized, no viable human embryo is created nor destroyed for the generation of ISCO’s hpSC lines. In addition, according to the Company, the histocompatibility profile of hpSCs makes this the only stem cell platform capable of generating stem cell lines that can immune-match millions of people. The main medical, economic, and ethical benefits of hpSCs are summarized in the Figure below.

The Company’s therapeutic efforts for its hpSCs are concentrated in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue:

  1. Parkinson’s disease;

  2. inherited metabolic liver disease; and

  3. corneal blindness.

ISCO believes these markets could have a combined revenue potential of over $5 billion. ISCO is also employing its proprietary stem cell technology to develop an stem cell bank, UniStemCell™, which already contains enough histocompatible stem cell lines to immune-match over 75 million people.

Revenue-Generating Therapeutic Programs

The Company produces and markets specialized cells and growth media for therapeutic research through its subsidiary Lifeline Cell Technology ( and SC-based skin care products through its subsidiary Lifeline Skin Care ( During 2012, these companies generated approximately $4.6 million in sales. 

Lifeline Cell Technology  is a B2B research products company that specializes in the development, manufacture, and commercialization of purified primary human cells, media, and reagents for cell culture and therapeutic research. Lifeline Cell Technology's line of biomedical products includes over 130 products in four categories: (1) human cells; (2) human tissues; (3) cell culture media; and (4) additional products such as reagents and SC differentiation kits. The products are used primarily for application in the field of regenerative medicine, safety and toxicology testing, and basic cell biology.  In 2012, Lifeline Cell Technology  generated $2.4 million in sales—a 35% growth rate over 2010.

Moreover, the Lifeline Skin Care subsidiary  develops, manufactures, and markets advanced anti-aging skin care products based on growth factors and peptides extracted from hpSCs. During development of its technology for therapeutic programs, ISCO scientists discovered that extracts from some stem cells had a beneficial effect on the health of skin cells. After additional experiments and collaborations with skin care experts in order to optimize the SC extract and formulation, the Lifeline Skin Care products were introduced in November 2010. Lifeline Skin Care products generated sales of $2.2 million in 2012.

Business Model and Growth Strategy

ISCO uses its proprietary platform technology to operate under a novel business model for the biotechnology industry (see ISCO'S Business Model below). Specifically, the revenue-generating commercial operations of its subsidiary businesses (Lifeline Cell Technology and Lifeline Skin Care) support the development of the Company’s therapeutic programs and licensing opportunities. This model not only provides practical, short-term applications of the Company’s core technologies, but also generates financial resources to support further scientific research and development of ISCO’s therapeutic programs in Parkinson’s disease, metabolic liver disease, and corneal blindness. In addition, ISCO’s plans include the creation of an SC bank and, once it has proven the technology platform by developing the therapeutic treatments, the licensing of its technologies to third parties for the development of third-party treatments. 


Learn More About International Stem Cell Corporation

Crystal Research has published a 72-page Executive Information Overview® on International Stem Cell Corporation, which overviews the Company's products and technologies, as well as its growth strategy, intellectual property, management, competition, among other relevant information. A free copy of the report can be downloaded via ISCO's Corporate Profile

Follow Crystal Research on LinkedIn, Twitter (@CrystalResearch) or Facebook to be among the first to hear about new published research on ISCO as well as for updates on International Stem Cell Corporation's latest developments.  

Read More

Topics: ISCO, New Research

AtheroNova Initiates Phase I Trial of AHRO-001

Posted by Colleen Koski

June 25, 2013 at 12:50 PM

Today, AtheroNova Inc. (AHRO-OTC) announced that it has initiated a Phase I clinical trial with AHRO-001, the Company’s lead compound. This milestone marks AtheroNova’s transition to a clinical-stage company. AHRO-001 is intended to treat and prevent atherosclerosis, a disease in which the buildup of cholesterol, fats, or other fatty substances along the walls of the arteries causes thickening, blockage, and hardening. Atherosclerotic plaque is the main cause of cardiovascular disease. 

Currently, lipid regulators, specifically statins, are the most effective method for reducing serum cholesterol levels. However, at commonly prescribed dosage levels, statins are ineffective at reducing plaque, carry significant drawbacks in their tolerability, and may pose complications resulting from long-term use. Despite these disadvantages, the global market for lipid regulators was $38.7 billion as of 2011 (Source: IMS Health).

Read More

Topics: AtheroNova, Newsworthy Events

Crystal Research Enters into Strategic Partnership with MZ Group

Posted by Colleen Koski

May 22, 2013 at 9:33 AM

"We are very excited to partner with a great organization like Crystal Research. With fewer sell-side firms capable and willing to provide research coverage for small and microcap stocks, we see tremendous value in independent research. After seeing Jeff and his team work with a few of our clients, we were extremely impressed with their diligent process and comprehensive reports. Forming this partnership allows us to leverage our collective strengths to help investors fully understand our client's stories and to increase investor and media awareness and interest in our client's companies."


Read More

Topics: Crystal Research Associates, MZ Group

MetaStat Focuses on Lead Product Opportunity and Bolstering Pipeline

Posted by Colleen Koski

April 19, 2013 at 9:13 AM

Yesterday, Crystal Research Associates published a 12-page Quarterly Update on MetaStat, Inc., a life sciences company developing next-generation diagnostic and therapeutic products for metastatic cancer. MetaStat is currently focused on three key initiatives within its pipeline: two diagnostic platforms (MetaSite™ Breast and MenaCalc™) as well as one therapeutic program (MenaBloc™). These candidates are overviewed on pages 5-8 of MetaStat's Quarterly Update.

Key Developments

Read More

Topics: MetaStat

NEW RESEARCH: Quarterly Update on AtheroNova Inc.

Posted by Colleen Koski

February 1, 2013 at 10:51 AM

Crystal Research Associates has released a Quarterly Update on AtheroNova Inc., a biotechnology company focused on the research and development of compounds that safely regress atherosclerotic plaque and improve patients’ lipid profiles. The 12-page report is available here.

Atherosclerotic plaque is a buildup of fat, cholesterol, and other substances. These plaque deposits, which progressively narrow and block the arteries, are the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD). 

Read More

Topics: AtheroNova, New Research

New Research: Report on MetaStat, Inc. (MTST-OTC.BB)

Posted by Colleen Koski

January 9, 2013 at 12:23 PM

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on
MetaStat, Inc.

Read More

Topics: MetaStat

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic